Looking at the universe of stocks we cover at Dividend Channel, on 3/29/18, Urstadt Biddle Properties Inc (UBP - Get Report) will trade ex-dividend, for its quarterly dividend of $0.24, payable on 4/16/18. As a percentage of UBP's recent stock price of $16.50, this dividend works out to approximately 1.45%, so look for shares of Urstadt Biddle Properties Inc to trade 1.45% lower — all else being equal — when UBP shares open for trading on 3/29/18.Below is a dividend history chart for UBP, showing historical dividends prior to the most recent $0.24 declared by Urstadt Biddle Properties Inc: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from UBP is likely to continue, and whether the current estimated yield of 5.82% on annualized basis is a reasonable expectation of annual yield going forward. The chart below shows the one year performance of UBP shares, versus its 200 day moving average: Looking at the chart above, UBP's low point in its 52 week range is $15.36 per share, with $18.92 as the 52 week high point — that compares with a last trade of $16.50. According to Preferred Stock Channel, there are 4 series of preferred stock that are senior to UBP — find out what they are ». In Tuesday trading, Urstadt Biddle Properties Inc shares are currently off about 2.8% on the day.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Iridium Communications Shows Long-Term, Upside Potential
Patient investors in Iridium have done well as the stock has rebounded from its 2016 lows.
Mallinckrodt Tumbles After Filing a Lawsuit Against the HHS on Acthar Gel
The drugmaker files suit against the U.S. Department of Health and Human Services and Centers for Medicare and Medicaid Services in order to protect Medicaid patient access to its Acthar gel.